Background: Teduglutide (Gattex; NPS Pharma, Bedminster, NJ), a recombinant analogue of human glucagon-like peptide 2 (GLP-2), is the first long-term medical therapy approved for the treatment of adults dependent on parenteral nutrition (PN). Objective: To assess the efficacy and safety of teduglutide in reducing PN (parenteral nutrient and/or fluid) requirements in PN-dependent adults. Methods: Studies were identified using predefined search criteria and multiple databases, including Medline and Embase. The search was completed to November 30, 2014, in the absence of date or study design restrictions. Citation inclusion criteria and methodological quality were assessed by 2 independent reviewers. Outcomes of interest were changes in parenteral nutrient or fluid requirements and adverse event incidence. From 2693 unique citations, 76 abstracts were reviewed. Fourteen reports met the inclusion criteria, including data from 2 phase III, double-blind, placebo-controlled clinical trials and their respective extension studies. Data extraction was performed by 2 reviewers using a standardized form. Results: Teduglutide reduced PN requirements compared with placebo, whereas adverse event incidence was similar. Limitations: Number of subjects studied and length of follow-up. Conclusions: Teduglutide appears to be a safe and well-tolerated means to reduce PN dependence in adults, regardless of PN dependence duration.
O’KeefeSBuchmanAFishbeinTJeejeebhoyKNJeppesenPBShafferJ. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4:6-10.
2.
BaxterJFayersPMcKinlayA. A review of the quality of life of adult patients treated with long-term parenteral nutrition. Clin Nutr. 2006;25:543-553.
3.
CarlssonEBosaeusINordgrenS. Quality of life and concerns in patients with short bowel syndrome. Clin Nutr. 2003;22:445-452.
4.
KalaitzakisECarlssonEJosefssonABosaeusI. Quality of life in short bowel syndrome: impact of fatigue and gastrointestinal symptoms. Scand J Gastroenterol. 2008;43:1057-1065.
5.
JeppesenPLangholzEMortensenP. Quality of life in patients receiving home parenteral nutrition. Gut. 1999;44:844-852.
6.
Huisman-de WaalGSchoonhovenLJansenJWantenGvan AchterbergT. The impact of home parenteral nutrition on daily life: a review. Clin Nutr. 2007;26:275-288.
7.
WinklerMHaganEWetleT. An exploration of quality of life and the experience of living with home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34:395-407.
8.
HowardLAshleyC. Management of complications in patients receiving home parenteral nutrition. Gastroenterology. 2003;124:1651-1661.
9.
PironiLJolyFForbesA. Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. Gut. 2011;60:17-25.
10.
American Gastroenterological Association. Short bowel syndrome and intestinal transplantation: medical position statement. Gastroenterology. 2003;124:1105-1110.
11.
JeppesenPStaunMMortensenP. Adult patients receiving home parenteral nutrition in Denmark from 1991 to 1996: who will benefit from intestinal transplantation?Scand J Gastroenterol. 1998;33:839-846.
12.
PironiLGouletOBuchmanA. Outcome on home parenteral nutrition for benign intestinal failure: a review of the literature and benchmarking with the European prospective survey of ESPEN. Clin Nutr. 2012;31:831-845.
13.
BuchmanAScolapioJFryerJ. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124:1111-1134.
14.
BuchmanA. The medical and surgical management of short bowel syndrome. MedGenMed. 2004;6:12.
15.
DruckerDDeForestLBrubakerP. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol. 1997;273:G1252-G1262.
16.
YazbeckRHowarthGAbbottC. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?Cytokine Growth Factor Rev. 2009;20:175-184.
17.
AlpersD. How adaptable is the intestine in patients with short bowel syndrome?Am J Clin Nutr. 2002;75:787-788.
18.
SundaramAKoutkiaPApovianC. Nutritional management of short bowel syndrome in adults. J Clin Gastroenterol. 2002;34:207-220.
19.
MessingBCrennPBeauPBoutronMRambaudJMatuchanskyC. Long-term survival and parenteral nutrition-dependency of adult patients with nonmalignant short bowel. Transplant Proc. 1998;30:2548.
20.
AmiotAMessingBCorcosOPanisYJolyF. Determinants of home parenteral nutrition dependence and survival of 268 patients with nonmalignant short bowel syndrome. Clin Nutr. 2013;32:368-374.
21.
PironiLForbesAJolyF. Survival of patients identified as candidates for intestinal transplantation: a 3-year prospective follow-up. Gastroenterology. 2008;135:61-71.
DruckerDErlichPAsaSBrubakerP. Induction of intestinal epithelial proliferation by glucagon-like peptide-2. Proc Nat Acad Sci USA. 1996;93(15):7911-7916.
24.
LitvakDHellmichMEversBBankerNTownsendCJr.. Glucagon-like peptide-2 is a potent growth factor for small intestine and colon. J Gastrointest Surg. 1998;2(2):146-150.
25.
TsaiCHillMAsaSBrubakerPDruckerD. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol. 1997;273(1, pt 1):E77-E84.
26.
BurrinDStollBGuanXCuiLChangXHolstJJ. Glucagon-like peptide-2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1):22-32.
27.
JeppesenPLundPGottschalckI. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract. 2009;2009:616054.
28.
CaniPPossemiersSVandeWieleT. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091-1103.
BremholmLHornumMAndersenUHartmannBHolstJJJeppesenPB. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept. 2011;168:32-38.
31.
HoyerupPHellstromPSchmidtP. Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients. Regul Pept. 2013;180:12-16.
32.
JeppesenPHartmannBThulesenJ. Glucagon-like peptide-2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120(4):806-815.
33.
MarierJBeliveauMMouksassiM. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48:1289-1299.
34.
MarierJMouksassiMGosselinNBeliveauMCyranJWallensJ. Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn’s disease. J Clin Pharmacol. 2010;50:36-49.
JeppesenP. New approaches to the treatments of short bowel syndrome-associated intestinal failure. Curr Opin Gastroenterol. 2014;30:182-188.
37.
HigginsJGreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Oxford, UK: The Cochrane Collaboration; 2011.
38.
GilroyRAllardJJeppesenP. Treatment out to 1 year with a GLP-2 analog, teduglutide, safely reduces parenteral nutrition (PN) needs in PN-dependent short bowel syndrome (SBS) patients. Am J Gastroenterol. 2008;103:S105-S106.
39.
JeppesenPTappendenKGilroyR. Teduglutide, a novel GLP-2 analogue, decreases fecal wet weight, sodium and potassium excretion in short bowel syndrome (SBS) patients dependent on parenteral nutrition (PN). Gastroenterology. 2009;136(5):A139.
40.
JeppesenPO’KeefeSGilroyRSeidnerDMessingB. Teduglutide (TG) improves electrolyte and wet weight absorption in short bowel syndrome (SBS) patients, but this is not correlated to increases in plasma citrulline (PC). Am J Gastroenterol. 2009;104:S409.
41.
JeppesenPTappendenKGilroyR. The influence of teduglutide, a novel GLP-2 analogue, on energy absorption in short bowel syndrome (SBS) patients dependent on parenteral nutrition (PN). Gastroenterology. 2009;136(5):A539.
42.
JeppesenPFujiokaKYoussefNNO’KeefeSJ. Long-term safety and efficacy of teduglutide treatment for intestinal failure associated with short bowel syndrome (SBS-IF): final results of a 2-year multicenter, open-label, clinical trial. Clin Nutr. 2014;33(suppl 1):S167.
43.
JeppesenPBFujiokaKYoussefNNO’KeefeSJ. Safety and efficacy of long-term teduglutide treatment: findings from a 2-year, open-label extension trial, STEPS-2. United Eur Gastroenterol J. 2014;2(A1):A111.
44.
IyerKFujiokaKBoullataJIZieglerTRYoussefNNSeidnerD. Safety and efficacy of long-term teduglutide for patients with short bowel syndrome and intestinal failure: final results of the STEPS-3 study. United Eur Gastroenterol J. 2014;2(A1):A111.
45.
FujiokaKPertkiewiczMGabeSYoussefNNJeppesenPB. Final results of STEPS-2, a 2-year multicenter open-label clinical trial: safety and efficacy of long-term teduglutide 0.05 mg/kg/day treatment for intestinal failure associated with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014;38(1):138-139.
46.
CompherCGilroyRPertkiewiczM. Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2011;35(5):603-609.
47.
UklejaAAlvarezAAlvarezKLaraL. Teduglutide for patients with short bowel syndrome: a single center experience. Clin Nutr. 2014;33(suppl 1):S178.
48.
JeppesenPGilroyRPertkiewiczM. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902-914.
49.
O’KeefeSJeppesenPGilroyRPertkiewiczMAllardJPMessingB. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013;11(7):815-823.
50.
JeppesenPPertkiewiczMMessingB. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.
51.
CrennPMatuchanskyCMessingB. Clinical and biochemical modelization of postsurgical intestinal failure in human adults. Clin Nutr. 1997;16:133-135.
52.
TappendenKEdelmanJJoelssonB. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013;47(7):602-607.
53.
JeppesenPSanguinettaEBuchmanA. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide-2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224-1231.
54.
BuchmanA. Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night. Gastroenterology. 2012;143:1416-1420.
55.
JeppesenPPertkiewiczMForbesA. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide—analyses from a randomised, placebo-controlled study. Clin Nutr. 2013;32(5):713-721.
56.
JeppesenPLundPGottschalckI. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol Res Pract. 2009;2009:425759.
57.
O’KeefeSGilroyRJeppesenP. Teduglutide, a novel GLP-2 analog, in the management of short bowel syndrome (SBS) patients dependent on parenteral nutrition: a multicenter, multinational placebo-controlled clinical trial. Gastroenterology. 2008;134(4):A37.
VipperlaKO’KeefeS. Teduglutide for the treatment of short bowel syndrome. Expert Rev Gastroenterol Hepatol. 2011;5:665-678.
60.
ThymannTStollBMecklenburgL. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in newborn pigs with short bowel syndrome. J Pediatr Gastroenterol Nutr. 2014;58(6):694-702.
61.
ColeCKocoshisS. Nutrition management of infants with surgical short bowel syndrome and intestinal failure. Nutr Clin Pract. 2013;28(4):421-428.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
